Literature DB >> 33055504

Urine Biomarker Assessment of Infant Adherence to Isoniazid Prophylaxis.

Sylvia M LaCourse1,2, Daniel Leon3, Nuttada Panpradist3, Barbra A Richardson2,4, Elizabeth Maleche-Obimbo5, Jerphason Mecha6, Daniel Matemo6, Jaclyn N Escudero2, John Kinuthia6,7, Barry Lutz2,3, Grace John-Stewart1,2,8,9.   

Abstract

We assessed adherence in an infant tuberculosis prevention trial in Kenya with a urine isoniazid metabolite-detecting dipstick. Ninety-seven infants had 155 assays performed; 77 (49.7%) were found to be positive despite caregiver-reported adherence. Positive assays were associated with maternal secondary education, HIV suppression and no reported missed doses in past 3 days, suggesting caregiver education and self-medication use influenced infant adherence.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33055504      PMCID： PMC8336467          DOI： 10.1097/INF.0000000000002936

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


  17 in total

1.  Urine testing to monitor adherence to TB preventive therapy.

Authors:  Sharon Perry; Melbourne F Hovell; Elaine Blumberg; Jill Berg; Alicia Vera; Carol Sipan; Norma Kelley; Kathleen Moser; Antonino Catanzaro; Larry Friedman
Journal:  J Clin Epidemiol       Date:  2002-03       Impact factor: 6.437

2.  Use of the urine color test to monitor compliance with isoniazid treatment of latent tuberculosis infection.

Authors:  Tal Eidlitz-Markus; Avraham Zeharia; Gerald Baum; Marc Mimouni; Jacob Amir
Journal:  Chest       Date:  2003-03       Impact factor: 9.410

3.  A Randomized Controlled Trial of Isoniazid to Prevent Mycobacterium tuberculosis Infection in Kenyan Human Immunodeficiency Virus-Exposed Uninfected Infants.

Authors:  Sylvia M LaCourse; Barbra A Richardson; John Kinuthia; A J Warr; Elizabeth Maleche-Obimbo; Daniel Matemo; Lisa M Cranmer; Jerphason Mecha; Jaclyn N Escudero; Thomas R Hawn; Grace John-Stewart
Journal:  Clin Infect Dis       Date:  2021-07-15       Impact factor: 9.079

4.  Isoniazid/acetylisoniazid urine concentrations: markers of adherence to isoniazid preventive therapy in children.

Authors:  V Amlabu; C Mulligan; N Jele; A Evans; D Gray; H J Zar; H McIlleron; P Smith
Journal:  Int J Tuberc Lung Dis       Date:  2014-05       Impact factor: 2.373

5.  Point-of-care Arkansas method for measuring adherence to treatment with isoniazid.

Authors:  Renata L Guerra; Marcus B Conde; Anne Efron; Carla Loredo; Gisele Bastos; Richard E Chaisson; Jonathan E Golub
Journal:  Respir Med       Date:  2010-03-03       Impact factor: 3.415

6.  Burden of childhood tuberculosis in 22 high-burden countries: a mathematical modelling study.

Authors:  Peter J Dodd; Elizabeth Gardiner; Renia Coghlan; James A Seddon
Journal:  Lancet Glob Health       Date:  2014-07-08       Impact factor: 26.763

7.  The value of urine testing for verifying adherence to anti-tuberculosis chemotherapy in children and adults in Uganda.

Authors:  P E Meissner; P Musoke; A Okwera; J E G Bunn; J B S Coulter
Journal:  Int J Tuberc Lung Dis       Date:  2002-10       Impact factor: 2.373

8.  Isoniazid preventive treatment among child contacts of adults with smear-positive tuberculosis in The Gambia.

Authors:  U Egere; A Sillah; T Togun; S Kandeh; F Cole; A Jallow; A Able-Thomas; M Hoelscher; N Heinrich; P C Hill; B Kampmann
Journal:  Public Health Action       Date:  2016-12-21

9.  Adherence to tuberculosis preventive therapy measured by urine metabolite testing among people with HIV.

Authors:  Emily A Kendall; Betina Durovni; Neil A Martinson; Solange Cavalacante; Katlego Masonoke; Valeria Saraceni; Limakatso Lebina; Anne Efron; Silvia Cohn; Sandy Chon; Richard E Chaisson; David W Dowdy; Jonathan E Golub
Journal:  AIDS       Date:  2020-01-01       Impact factor: 4.632

10.  Adherence, tolerability, and outcome after 36 months of isoniazid-preventive therapy in 2 rural clinics of Swaziland: A prospective observational feasibility study.

Authors:  Yolanda Mueller; Qhubekani Mpala; Bernhard Kerschberger; Barbara Rusch; Gugu Mchunu; Sikhathele Mazibuko; Maryline Bonnet
Journal:  Medicine (Baltimore)       Date:  2017-09       Impact factor: 1.889
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.